NAPSR News: FDA Approves Spectrum's Beleodaq to Treat Rare Form of non-Hodgkin Lymphoma

Clinical data catapults FDA approval for belinostat, a new T-cell lymphoma drug that will be sold as Beleodaq from Spectrum Pharmaceuticals.



via Marketing - Latest News http://ift.tt/1jgN3Pv